Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
+0.77%
SPX
+0.83%
IXIC
+0.98%
FTSE
+0.42%
N225
+0.75%
AXJO
+0.45%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Stocks
0.00 (0.00%)
0.000
USD
At close at --,----
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

Join our newsletter to keep up to date with us!

Overview

Loading chart...

About

What does NBIX do?
Neurocrine Biosciences, based in San Diego, develops pharmaceuticals for neurological disorders and employs 1,448 people. Its FDA-approved products include INGREZZA and Orilissa, with a strong clinical development pipeline.
Sector
💻 Health Care
IPO
CEO
Employees
1,800
Headquarters
California, USA
Website
http://www.neurocrine.com

Key Stats

Market Cap
13.47B
Dividend Yield
0.00%
P/E Ratio
38.67
EPS
3.38
Revenue
2.36B
Avg. Volume
809.92K

Recently from Cashu

publisher logo
Cashu

Neurocrine Biosciences Engages Investors at Upcoming Healthcare Conferences in September 2025

7 days ago
publisher logo
Cashu

Neurocrine Biosciences Highlights Neuroscience Commitment at September 2025 Investor Conferences

8 days ago
publisher logo
Cashu

Neurocrine Biosciences (NBIX) Prepares for Key Investor Conferences in September 2025

10 days ago
Stocks
Health Care
nbix
Neurocrine Biosciences
NASDAQ: NBIX
+4.34 (+3.19%)
140.45
USD
At close at Sep 04, 20:37 UTC
Summary
News
Signals
Benchmarks
Financials